{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:43:31Z","timestamp":1788176611841,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00761-6","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:10:40Z","timestamp":1763691040000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rationale for the Use of Fixed Combination Therapies with Angiotensin Converting Enzyme Inhibitors and Beta-Blockers in Patients with Essential Hypertension and High Cardiovascular Risk: A Consensus Document from the Italian Society of Arterial Hypertension (Siia) and the Italian Society of Cardiovascular Prevention (SIPREC)"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-0223","authenticated-orcid":false,"given":"Agostino","family":"Virdis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0635-4921","authenticated-orcid":false,"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-9441","authenticated-orcid":false,"given":"Maria Lorenza","family":"Muiesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-1271","authenticated-orcid":false,"given":"GiovamBattista","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-7043","authenticated-orcid":false,"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-7667","authenticated-orcid":false,"given":"Fabio Lucio","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-0181","authenticated-orcid":false,"given":"Riccardo","family":"Sarzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Gallo","family":"Giovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-6547","authenticated-orcid":false,"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"9995","key":"761_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(14)61468-9","volume":"386","author":"NR Poulter","year":"2015","unstructured":"Poulter NR, Prabhakaran D, Caulfield M, Hypertension. Lancet. 2015;386(9995):801\u201312.","journal-title":"Lancet"},{"issue":"9438","key":"761_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"issue":"10199","key":"761_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S0140-6736(19)30955-9","volume":"394","author":"P Geldsetzer","year":"2019","unstructured":"Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1\u00b71 million adults. Lancet. 2019;394(10199):652\u201362.","journal-title":"Lancet"},{"issue":"20","key":"761_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2010.650","volume":"303","author":"BM Egan","year":"2010","unstructured":"Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008. JAMA. 2010;303(20):2043\u201350.","journal-title":"JAMA"},{"issue":"9","key":"761_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959\u201368.","journal-title":"JAMA"},{"issue":"4","key":"761_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/jhh.2016.71","volume":"31","author":"G Tocci","year":"2017","unstructured":"Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258\u201362.","journal-title":"J Hum Hypertens"},{"issue":"10199","key":"761_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0140-6736(19)31145-6","volume":"394","author":"(NCD-RisC) NRFC","year":"2019","unstructured":"(NCD-RisC) NRFC. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639\u201351.","journal-title":"Lancet"},{"issue":"8","key":"761_CR8","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/HJH.0000000000000222","volume":"32","author":"G Mancia","year":"2014","unstructured":"Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32(8):1708\u201315. discussion 16.","journal-title":"J Hypertens"},{"issue":"6","key":"761_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40292-020-00420-y","volume":"27","author":"G Tocci","year":"2020","unstructured":"Tocci G, Presta V, Citoni B, Figliuzzi I, Bianchi F, Ferrucci A, et al. Blood pressure target achievement under monotheraphy: a Real-Life appraisal. High Blood Press Cardiovasc Prev. 2020;27(6):587\u201396.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"761_CR10","doi-asserted-by":"crossref","unstructured":"Del Pinto R, Agabiti Rosei C, Borghi C, Cipollini F, Cottone S, De Giorgi GA, et al. May measure month 2022 in italy: A focus on Fixed-dose Combination, therapeutic Adherence, and medical inertia in a nationwide survey. High Blood Press Cardiovasc Prev 2024;31(3):309\u2013320","DOI":"10.1007\/s40292-024-00642-4"},{"issue":"6","key":"761_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.numecd.2020.03.005","volume":"30","author":"AFG Cicero","year":"2020","unstructured":"Cicero AFG, Fogacci F, Tocci G, Ventura F, Presta V, Grandi E, et al. Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: data from the Brisighella heart study. Nutr Metab Cardiovasc Dis. 2020;30(6):907\u201314.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"761_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jch.12711","volume":"18","author":"G Tocci","year":"2016","unstructured":"Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, Ferri C, Virdis A, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 during world hypertension day in Italy. J Clin Hypertens (Greenwich). 2016;18(6):551\u20136.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"761_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846\u201353.","journal-title":"Hypertension"},{"issue":"3","key":"761_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","volume":"29","author":"G Corrao","year":"2011","unstructured":"Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610\u20138.","journal-title":"J Hypertens"},{"issue":"1","key":"761_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40292-013-0007-2","volume":"20","author":"M Volpe","year":"2013","unstructured":"Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. 2012 consensus document of the Italian society of hypertension (SIIA): strategies to improve blood pressure control in italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1):45\u201352.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"761_CR16","doi-asserted-by":"crossref","unstructured":"Mancia Chairperson G, Kreutz Co-Chair R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension endorsed by the European renal association (ERA) and the international society of hypertension (ISH). J Hypertens. 2023;41(12):1874\u20132071.","DOI":"10.1097\/HJH.0000000000003480"},{"issue":"38","key":"761_CR17","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"key":"761_CR18","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC et al. \/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;152:e114\u2013e218."},{"issue":"36","key":"761_CR19","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"10","key":"761_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/ajh.2011.105","volume":"24","author":"M Volpe","year":"2011","unstructured":"Volpe M, Tocci G. Redefining blood pressure targets in high-risk patients? Lessons from coronary endpoints in recent randomized clinical trials. Am J Hypertens. 2011;24(10):1060\u20138.","journal-title":"Am J Hypertens"},{"issue":"10285","key":"761_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"BPLTT Collaboration","year":"2021","unstructured":"Collaboration BPLTT. Pharmacological blood pressure Lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.","journal-title":"Lancet"},{"issue":"12","key":"761_CR22","first-page":"CD004349","volume":"12","author":"JA Arguedas","year":"2020","unstructured":"Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020;12(12):CD004349.","journal-title":"Cochrane Database Syst Rev"},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.ijchy.2020.100040","volume":"6","author":"B Baffour-Awuah","year":"2020","unstructured":"Baffour-Awuah B, Dieberg G, Pearson MJ, Smart NA. Blood pressure control in older adults with hypertension: a systematic review with meta-analysis and meta-regression. Int J Cardiol Hypertens. 2020;6:100040.","journal-title":"Int J Cardiol Hypertens"},{"issue":"4","key":"761_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11886-010-0112-y","volume":"12","author":"P Verdecchia","year":"2010","unstructured":"Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Garofoli M, Martire P, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep. 2010;12(4):302\u20136.","journal-title":"Curr Cardiol Rep"},{"issue":"10056","key":"761_CR25","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","volume":"388","author":"E Vidal-Petiot","year":"2016","unstructured":"Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142\u201352.","journal-title":"Lancet"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diabres.2019.01.031","volume":"149","author":"K Kamishima","year":"2019","unstructured":"Kamishima K, Ogawa H, Jujo K, Yamaguchi J, Hagiwara N. Relationships between blood pressure Lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: the HIJ-CREATE sub-study. Diabetes Res Clin Pract. 2019;149:69\u201377.","journal-title":"Diabetes Res Clin Pract"},{"issue":"25","key":"761_CR27","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"collaboration SwgaECr","year":"2021","unstructured":"collaboration SwgaECr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J"},{"issue":"25","key":"761_CR28","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","volume":"42","author":"collaboration S-OwgaECr","year":"2021","unstructured":"collaboration S-OwgaECr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455\u201367.","journal-title":"Eur Heart J"},{"issue":"28","key":"761_CR29","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"S-DWGECR Collaboration","year":"2023","unstructured":"Collaboration S-DWGECR. SCORE2-Diabetes: 10-year cardiovascular risk Estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544\u201356.","journal-title":"Eur Heart J"},{"issue":"23","key":"761_CR30","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"Major outcomes in","year":"2002","unstructured":"Major outcomes in. high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981\u201397.","journal-title":"JAMA"},{"issue":"9489","key":"761_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus Atenolol adding Bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes Trial-Blood pressure Lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"761_CR32","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or Hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"761_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290\u2013300.","journal-title":"Am J Med"},{"issue":"7404","key":"761_CR34","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure Lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.","journal-title":"BMJ"},{"key":"761_CR35","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.5646\/ch.2025.31.e25","volume":"31","author":"S Park","year":"2025","unstructured":"Park S, Shin ES, Ihm SH, Lee HY. Optimizing systolic blood pressure targets for elderly hypertensive patients: a meta-analysis of mortality, cardiovascular outcomes, and adverse events. Clin Hypertens. 2025;31:e25.","journal-title":"Clin Hypertens"},{"issue":"8","key":"761_CR36","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/HJH.0000000000001777","volume":"36","author":"C Thomopoulos","year":"2018","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637\u201347.","journal-title":"J Hypertens"},{"issue":"6","key":"761_CR37","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/HJH.0000000000002760","volume":"39","author":"G Mancia","year":"2021","unstructured":"Mancia G, Masi S, Palatini P, Tsioufis C, Grassi G. Elevated heart rate and cardiovascular risk in hypertension. J Hypertens. 2021;39(6):1060\u20139.","journal-title":"J Hypertens"},{"issue":"3","key":"761_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353.","journal-title":"N Engl J Med"},{"issue":"23","key":"761_CR39","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"Trial AOaCftACRGTAaL-LTtPHA","year":"2002","unstructured":"Trial AOaCftACRGTAaL-LTtPHA. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981\u201397.","journal-title":"JAMA"},{"issue":"9489","key":"761_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus Atenolol adding Bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes Trial-Blood pressure Lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"761_CR41","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, et al. Benazepril plus amlodipine or Hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"9080","key":"761_CR42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenh\u00e4ger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997;350(9080):757\u201364.","journal-title":"Lancet"},{"issue":"18","key":"761_CR43","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887\u201398.","journal-title":"N Engl J Med"},{"issue":"9590","key":"761_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of Perindopril and Indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829\u201340.","journal-title":"Lancet"},{"issue":"9463","key":"761_CR45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939\u201346.","journal-title":"Lancet"},{"issue":"9638","key":"761_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"issue":"9287","key":"761_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PC Group","year":"2001","unstructured":"Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u201341.","journal-title":"Lancet"},{"issue":"9386","key":"761_CR48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, Investigators EtOrocewPiscAd. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782\u20138.","journal-title":"Lancet"},{"issue":"20","key":"761_CR49","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"E Braunwald","year":"2004","unstructured":"Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme Inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058\u201368.","journal-title":"N Engl J Med"},{"issue":"2","key":"761_CR50","doi-asserted-by":"publisher","first-page":"A60","DOI":"10.1016\/S0002-9149(88)80087-0","volume":"62","author":"K Swedberg","year":"1988","unstructured":"Swedberg K, Kjekshus J. Effects of Enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian Enalapril survival study (CONSENSUS). Am J Cardiol. 1988;62(2):A60\u20136.","journal-title":"Am J Cardiol"},{"issue":"11","key":"761_CR51","doi-asserted-by":"publisher","first-page":"40D","DOI":"10.1016\/0002-9149(90)90475-G","volume":"66","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of Enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS trial study group. Am J Cardiol. 1990;66(11):40D. 4D; discussion 4D-5D.","journal-title":"Am J Cardiol"},{"issue":"10","key":"761_CR52","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Yusuf","year":"1992","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN, Investigators S. Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685\u201391.","journal-title":"N Engl J Med"},{"issue":"8829","key":"761_CR53","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","volume":"340","author":"S Yusuf","year":"1992","unstructured":"Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of Enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340(8829):1173\u20138.","journal-title":"Lancet"},{"issue":"4","key":"761_CR54","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1161\/01.CIR.90.4.1731","volume":"90","author":"JD Rutherford","year":"1994","unstructured":"Rutherford JD, Pfeffer MA, Moy\u00e9 LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of Captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators Circulation. 1994;90(4):1731\u20138.","journal-title":"SAVE Investigators Circulation"},{"issue":"9215","key":"761_CR55","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","volume":"355","author":"MD Flather","year":"2000","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor myocardial infarction collaborative group. Lancet. 2000;355(9215):1575\u201381.","journal-title":"Lancet"},{"key":"761_CR56","doi-asserted-by":"publisher","first-page":"j4","DOI":"10.1136\/bmj.j4","volume":"356","author":"S Bangalore","year":"2017","unstructured":"Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:j4.","journal-title":"BMJ"},{"issue":"3","key":"761_CR57","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","volume":"14","author":"JF Mann","year":"2003","unstructured":"Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003;14(3):641\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"761_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajkd.2003.07.015","volume":"42","author":"JF Mann","year":"2003","unstructured":"Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the heart outcomes and prevention evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42(5):936\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"761_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40292-024-00687-5","volume":"32","author":"A Manolis","year":"2025","unstructured":"Manolis A, Karakasis P, Patoulias D, Doumas M, Kallistratos M, Thomopoulos C, et al. Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials. High Blood Press Cardiovasc Prev. 2025;32(1):7\u201331.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"761_CR60","doi-asserted-by":"crossref","unstructured":"Chen JM, Heran BS, Perez MI, Wright JM. Blood pressure Lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2010;2010(1):CD007185.","DOI":"10.1002\/14651858.CD007185.pub2"},{"issue":"5","key":"761_CR61","first-page":"7270","volume":"8","author":"H Guo","year":"2015","unstructured":"Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med. 2015;8(5):7270\u20138.","journal-title":"Int J Clin Exp Med"},{"issue":"9311","key":"761_CR62","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against Atenolol. Lancet. 2002;359(9311):995\u20131003.","journal-title":"Lancet"},{"issue":"9364","key":"761_CR63","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with Atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes Trial\u2013Lipid Lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet"},{"issue":"6","key":"761_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","volume":"12","author":"D Castagno","year":"2010","unstructured":"Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F, et al. Improved survival with Bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency Bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail. 2010;12(6):607\u201316.","journal-title":"Eur J Heart Fail"},{"issue":"9146","key":"761_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"The Cardiac Insufficiency Bisoprolol Study II","year":"1999","unstructured":"The Cardiac Insufficiency Bisoprolol Study II. (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313.","journal-title":"Lancet"},{"issue":"9169","key":"761_CR66","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure. Metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20137.","journal-title":"Lancet"},{"issue":"17","key":"761_CR67","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194\u20139.","journal-title":"Circulation"},{"issue":"3","key":"761_CR68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215\u201325.","journal-title":"Eur Heart J"},{"issue":"5","key":"761_CR69","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/HJH.0000000000000865","volume":"34","author":"P Palatini","year":"2016","unstructured":"Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, et al. Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European society of hypertension. J Hypertens. 2016;34(5):813\u201321.","journal-title":"J Hypertens"},{"issue":"2","key":"761_CR70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/HYPERTENSIONAHA.120.14804","volume":"76","author":"G Grassi","year":"2020","unstructured":"Grassi G, Quarti-Trevano F, Seravalle G, Dell\u2019Oro R, Facchetti R, Mancia G. Association between the European society of Cardiology\/European society of hypertension heart rate thresholds for cardiovascular risk and neuroadrenergic markers. Hypertension. 2020;76(2):577\u201382.","journal-title":"Hypertension"},{"issue":"9","key":"761_CR71","doi-asserted-by":"publisher","first-page":"e72102","DOI":"10.1371\/journal.pone.0072102","volume":"8","author":"WJ Zhou","year":"2013","unstructured":"Zhou WJ, Wang RY, Li Y, Chen DR, Chen EZ, Zhu DL, et al. A randomized controlled study on the effects of Bisoprolol and Atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS ONE. 2013;8(9):e72102.","journal-title":"PLoS ONE"},{"issue":"1","key":"761_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2016.101","volume":"40","author":"T Yang","year":"2017","unstructured":"Yang T, Jiang Y, Hao Y, Zhou S, Xu X, Qu B, et al. Comparison of Bisoprolol to a Metoprolol CR\/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017;40(1):79\u201386.","journal-title":"Hypertens Res"},{"issue":"4","key":"761_CR73","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10557-021-07248-1","volume":"37","author":"MH Strauss","year":"2023","unstructured":"Strauss MH, Hall AS, Narkiewicz K. The combination of Beta-Blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther. 2023;37(4):757\u201370.","journal-title":"Cardiovasc Drugs Ther"},{"key":"761_CR74","doi-asserted-by":"crossref","unstructured":"Doehner W, Boriani G, Potpara T, Blomstrom-Lundqvist C, Passman R, Sposato LA et al. Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European society of cardiology Council on stroke and the European heart rhythm association. Europace. 2025;27(3):euaf019.","DOI":"10.1093\/europace\/euaf019"},{"issue":"36","key":"761_CR75","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414.","journal-title":"Eur Heart J"},{"issue":"5","key":"761_CR76","first-page":"854","volume":"70","author":"MS Dzeshka","year":"2017","unstructured":"Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atr Fibrillation Hypertens Hypertens. 2017;70(5):854\u201361.","journal-title":"Atr Fibrillation Hypertens Hypertens"},{"issue":"12","key":"761_CR77","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1097\/HJH.0000000000003278","volume":"40","author":"ME Middeldorp","year":"2022","unstructured":"Middeldorp ME, Ariyaratnam JP, Kamsani SH, Albert CM, Sanders P. Hypertension and atrial fibrillation. J Hypertens. 2022;40(12):2337\u201352.","journal-title":"J Hypertens"},{"issue":"5","key":"761_CR78","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/europace\/euv021","volume":"17","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Callender T, Cao J, Rahimi K. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. Europace. 2015;17(5):701\u201310.","journal-title":"Europace"},{"issue":"4","key":"761_CR79","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1074248415619490","volume":"21","author":"S Chaugai","year":"2016","unstructured":"Chaugai S, Meng WY, Ali Sepehry A. Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and Meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2016;21(4):388\u2013404.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"761_CR80","doi-asserted-by":"crossref","unstructured":"Gewehr DM, Carvalho PEP, Martignoni FV, Nogueira A, Gomes C, Navalha DDP et al. Effect of antihypertensive agents on the risk of New-Onset and recurrent atrial fibrillation: a bayesian network Meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2025;1:zwaf335.","DOI":"10.1093\/eurjpc\/zwaf335"},{"issue":"4","key":"761_CR81","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","volume":"28","author":"IA Nasr","year":"2007","unstructured":"Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28(4):457\u201362.","journal-title":"Eur Heart J"},{"key":"761_CR82","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.1016\/j.phrs.2020.104785","volume":"156","author":"G Sinagra","year":"2020","unstructured":"Sinagra G, Corr\u00e0 U, Contini M, Magr\u00ec D, Paolillo S, Perrone Filardi P, et al. Choosing among \u03b2-blockers in heart failure patients according to \u03b2-receptors\u2019 location and functions in the cardiopulmonary system. Pharmacol Res. 2020;156:104785.","journal-title":"Pharmacol Res"},{"issue":"1","key":"761_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2024","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2024;26(1):5\u201317.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"761_CR84","first-page":"678","volume":"112","author":"S Calabria","year":"2021","unstructured":"Calabria S, Piccinni C, Ronconi G, Dondi L, Cinconze E, Esposito I, et al. [Chronic use of the unfixed combination of ACE-inhibitors and beta-blockers in Italy from 2013 to 2019 through the healthcare administrative data]. Recenti Prog Med. 2021;112(10):678\u201386.","journal-title":"Recenti Prog Med"},{"issue":"1","key":"761_CR85","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cts.13128","volume":"15","author":"J Sus","year":"2022","unstructured":"Sus J, Huguet J, Bosak J, Setnik B, Hauser T, Sicard E. The bioequivalence of fixed-dose combination tablets of Bisoprolol and Ramipril and its drug-drug interaction potential. Clin Transl Sci. 2022;15(1):158\u201371.","journal-title":"Clin Transl Sci"},{"issue":"34","key":"761_CR86","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00761-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:02:03Z","timestamp":1770552123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00761-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00761-6","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised for funding note added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present manuscript was partially supported by unrestricted research grant provided by Sandoz Italia S.p.A. to the Italian Society of Arterial Hypertension (SIIA) and the Italian\n                      Society\n                      of Cardiovascular Prevention (SIPREC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable for the contents of the present consensus document.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}